The FDA accepts Cerus' (CERS +5.9%) outline of its Premarket Approval application for the...

|About: Cerus Corporation (CERS)|By:, SA News Editor

The FDA accepts Cerus' (CERS +5.9%) outline of its Premarket Approval application for the INTERCEPT Blood System for platelets which is already in use by customers in 16 countries.